• Astellas' Prostate Cancer Drug Receives Priority FDA Approval

    A new drug manufactured by California-based Astellas Pharma promises to help treat aggressive, late-stage prostate cancer that has evaded other treatments, the US Food and Drug Administration (FDA) said in a statement approving the drug on 31 August. The drug, Xtandi (enzalutamide), was approved under FDA's priority review program, and was reviewed in just three months-half the time allotted to FDA under the priority review program. Xtandi was subject to a clinical tri...